Lassa fever: With 50 years of study, hundreds of thousands of patients and an extremely high disease burden, what have we learned?
Open Access
- 31 August 2019
- journal article
- research article
- Published by Elsevier BV in Current Opinion in Virology
- Vol. 37, 123-131
- https://doi.org/10.1016/j.coviro.2019.07.009
Abstract
No abstract availableKeywords
Funding Information
- Canadian Institutes of Health Research
- Government of Canada
This publication has 84 references indexed in Scilit:
- Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal ElectroporationVaccines, 2013
- Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infectionVirology Journal, 2011
- Pathogenesis of lassa fever in cynomolgus macaquesVirology Journal, 2011
- Decoding arenavirus pathogenesis: Essential roles for alpha-dystroglycan-virus interactions and the immune responseVirology, 2011
- Early and Strong Immune Responses Are Associated with Control of Viral Replication and Recovery in Lassa Virus-Infected Cynomolgus MonkeysJournal of Virology, 2009
- Characterization of Lassa Virus Cell Entry and Neutralization with Lassa Virus PseudoparticlesJournal of Virology, 2009
- Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primatesVaccine, 2008
- Lassa Virus Infection in Experimentally Infected Marmosets: Liver Pathology and Immunophenotypic Alterations in Target TissuesJournal of Virology, 2007
- A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunityVaccine, 2007
- Molecular characterization of a reassortant virus derived from Lassa and Mopeia virusesVirus Genes, 2006